In biotech, there’s a big difference between “trajectory” and “velocity.” Getting a drug to market quickly, after all, doesn’t always mean that you’re on the path to building a sustainable company. For your biotech to thrive over the long term, it’s critical to continue any forward momentum while ensuring you don’t run out of fuel halfway through your journey.
Summary: In this executive summary, industry experts share case studies of how they’ve adapted to increasingly expedited regulatory reviews.
Strategic analytical partnerships are important in the development of new pharmaceutical products, especially biologics. In this article, experts discuss the growing need for partners who can provide niche technologies to accelerate development projects.
This article explores the biologics landscape, market insights and trends, and provides future projections for what the global biologics market, including cell and gene therapy, will look like over the coming years.
This executive summary discusses imperative that companies invest adequate time and resources in strategic planning and preparation activities to ensure the best chances for a successful commercial launch.
